38 results
8-K
EX-99.1
NRIX
Nurix Therapeutics Inc
12 Apr 24
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
5:12pm
on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels
424B5
NRIX
Nurix Therapeutics Inc
12 Apr 24
Prospectus supplement for primary offering
5:10pm
of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer
424B5
NRIX
Nurix Therapeutics Inc
11 Apr 24
Prospectus supplement for primary offering
4:06pm
focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular
8-K
EX-99.1
NRIX
Nurix Therapeutics Inc
10 Apr 24
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
7:02am
of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer
8-K
EX-99.1
cfw7q 1crl266d
11 Mar 24
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
7:02am
8-K
EX-99.1
0y4wt0l3
15 Feb 24
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
4:01pm
8-K
EX-99.2
s0p311 npr
8 Jan 24
Regulation FD Disclosure
7:03am
8-K
EX-99.1
6denu09jlqgu
8 Jan 24
Regulation FD Disclosure
7:03am
8-K
EX-99.1
3435w56ai3z6ibu xl5
11 Dec 23
Other Events
12:03pm
8-K
EX-99.1
9w2b74d0i ktuk4q0
1 Nov 23
Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial
4:02pm
8-K
EX-99.1
z96bci5ii31mm54bj1b1
13 Jul 23
Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
4:18pm
8-K
EX-99.1
suy8pcypv0 g11oao
13 Apr 23
Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
4:02pm
8-K
EX-99.2
txnj udqsl6k
12 Dec 22
Other Events
5:36pm
8-K
EX-99.1
fv375 r8v6vw11
14 Sep 22
Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors
4:01pm